share_log

Amgen | 8-K: AMGEN REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS

Amgen | 8-K: AMGEN REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS

安進 | 8-K：安進公佈2024年第三季度財務業績
美股SEC公告 ·  2024/10/31 04:08

Moomoo AI 已提取核心訊息

Amgen delivered robust financial performance in Q3 2024, with total revenues increasing 23% to $8.5 billion. Product sales grew 24%, driven by 29% volume growth, partially offset by 2% lower net selling price. Excluding Horizon Therapeutics acquisition, product sales grew 8% with 12% volume growth.Ten products achieved double-digit sales growth, including Repatha (+40%), TEZSPIRE (+67%), and BLINCYTO (+49%). The rare disease portfolio contributed $1.2 billion in sales, led by TEPEZZA, KRYSTEXXA, UPLIZNA, and TAVNEOS. GAAP EPS increased 62% to $5.22, while non-GAAP EPS rose 13% to $5.58.The company generated $3.3 billion in free cash flow, up from $2.5 billion in Q3 2023. For full-year 2024, Amgen expects total revenues of $33.0-33.8 billion and non-GAAP EPS of $19.20-20.00. The company reduced principal debt by $2.5 billion in Q3, bringing year-to-date debt reduction to $4.5 billion.
Amgen delivered robust financial performance in Q3 2024, with total revenues increasing 23% to $8.5 billion. Product sales grew 24%, driven by 29% volume growth, partially offset by 2% lower net selling price. Excluding Horizon Therapeutics acquisition, product sales grew 8% with 12% volume growth.Ten products achieved double-digit sales growth, including Repatha (+40%), TEZSPIRE (+67%), and BLINCYTO (+49%). The rare disease portfolio contributed $1.2 billion in sales, led by TEPEZZA, KRYSTEXXA, UPLIZNA, and TAVNEOS. GAAP EPS increased 62% to $5.22, while non-GAAP EPS rose 13% to $5.58.The company generated $3.3 billion in free cash flow, up from $2.5 billion in Q3 2023. For full-year 2024, Amgen expects total revenues of $33.0-33.8 billion and non-GAAP EPS of $19.20-20.00. The company reduced principal debt by $2.5 billion in Q3, bringing year-to-date debt reduction to $4.5 billion.
安進在2024年第三季度表現出色，總收入增長23%，達到85億。產品銷售增長24%，主要受到29%成交量增長的推動，部分被2%的淨售價降低所抵消。不考慮收購Horizon Therapeutics，產品銷售增長8%，成交量增長12%。十種產品實現了雙位數銷售增長，包括Repatha（+40%）、TEZSPIRE（+67%）和BLINCYTO（+49%）。罕見疾病產品組合貢獻了12億的銷售額，主要由TEPEZZA、KRYSTEXXA、UPLIZNA和TAVNEOS主導。GAAP每股收益增長62%，達5.22美元，而非GAAP每股收益上升13%，達到5.58美元。公司產生了33億的自由現金流，較2023年第三季度的25億有所增加。對於2024年全年，安進預計總收入爲330-338億，非GAAP每股收益爲19.20-20.00美元。公司在第三季度減少了25億的本金債務，使得年初至今的債務減少總額達到45億。
安進在2024年第三季度表現出色，總收入增長23%，達到85億。產品銷售增長24%，主要受到29%成交量增長的推動，部分被2%的淨售價降低所抵消。不考慮收購Horizon Therapeutics，產品銷售增長8%，成交量增長12%。十種產品實現了雙位數銷售增長，包括Repatha（+40%）、TEZSPIRE（+67%）和BLINCYTO（+49%）。罕見疾病產品組合貢獻了12億的銷售額，主要由TEPEZZA、KRYSTEXXA、UPLIZNA和TAVNEOS主導。GAAP每股收益增長62%，達5.22美元，而非GAAP每股收益上升13%，達到5.58美元。公司產生了33億的自由現金流，較2023年第三季度的25億有所增加。對於2024年全年，安進預計總收入爲330-338億，非GAAP每股收益爲19.20-20.00美元。公司在第三季度減少了25億的本金債務，使得年初至今的債務減少總額達到45億。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間